| Title |
Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer
|
|---|---|
| Published in |
BMC Cancer, January 2014
|
| DOI | 10.1186/1471-2407-14-5 |
| Pubmed ID | |
| Authors |
Michael L Maitland, Matthew R Levine, Mario E Lacouture, Kristen E Wroblewski, Christine H Chung, Ilyssa O Gordon, Livia Szeto, Gail Ratko, Keyoumars Soltani, Mark F Kozloff, Philip C Hoffman, Ravi Salgia, David P Carbone, Theodore G Karrison, Everett E Vokes |
| Abstract |
Candidate predictive biomarkers for epidermal growth factor receptor inhibitors (EGFRi), skin rash and serum proteomic assays, require further qualification to improve EGFRi therapy in non-small cell lung cancer (NSCLC). In a phase II trial that was closed to accrual because of changes in clinical practice we examined the relationships among candidate biomarkers, quantitative changes in tumor size, progression-free and overall survival. |
Mendeley readers
The data shown below were compiled from readership statistics for 42 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 42 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 7 | 17% |
| Student > Master | 6 | 14% |
| Other | 5 | 12% |
| Researcher | 3 | 7% |
| Lecturer | 3 | 7% |
| Other | 9 | 21% |
| Unknown | 9 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 40% |
| Nursing and Health Professions | 7 | 17% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 5% |
| Unspecified | 1 | 2% |
| Psychology | 1 | 2% |
| Other | 3 | 7% |
| Unknown | 11 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 January 2014.
All research outputs
#20,215,721
of 22,738,543 outputs
Outputs from BMC Cancer
#6,489
of 8,272 outputs
Outputs of similar age
#264,486
of 304,891 outputs
Outputs of similar age from BMC Cancer
#86
of 104 outputs
Altmetric has tracked 22,738,543 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,272 research outputs from this source. They receive a mean Attention Score of 4.3. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 304,891 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 104 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.